Elutia (ELUT) Net Margin (2019 - 2026)

Elutia (ELUT) posted Net Margin of 13.65% for Q1 2026, down 97.44% sequentially from 533.92% in Q4 2025, and up 14692.0% YoY from N/an in Q1 2025.

Elutia (ELUT) Net Margin (2019 - 2026) Analysis & Trends

Elutia has reported Net Margin for 8 years, with the latest figure at 13.65% in Q1 2026.

Quarterly Net Margin rose 14692.0% year-over-year to 13.65% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 27.62% (down 6009.0% YoY) and the FY2025 annual result came in at 0.43%, up 81.0% from the prior year.
Net Margin declined to 13.65% in Q1 2026 per ELUT's latest filing, from 533.92% in the prior quarter.
Over five years, Net Margin peaked at 1592.12% in Q4 2024 and troughed at 447.94% in Q2 2024.
A 5-year average of 1.23% and a median of 121.71% in 2023 frame the typical range for Net Margin.
The sharpest annual moves came in 2024 and 2025: Net Margin jumped 181181 bps in 2024, then sank 105820 bps in 2025.
Over 5 years, Net Margin stood at 82.59% in 2022, then sank by 166 bps to 219.69% in 2023, then jumped by 825 bps to 1592.12% in 2024, then tumbled by 66 bps to 533.92% in 2025, then slumped by 97 bps to 13.65% in 2026.
According to Business Quant data, Net Margin over the past three periods registered 13.65%, 533.92%, and 116.4% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Abbott Laboratories	202.61 Bn	197.01 Bn	7.27 Bn	7.37%
2	Stryker	126.60 Bn	123.12 Bn	4.50 Bn	19.37%
3	Medtronic	119.39 Bn	110.17 Bn	6.41 Bn	12.84%
4	Boston Scientific	74.22 Bn	73.68 Bn	3.85 Bn	16.67%
5	Edwards Lifesciences	51.66 Bn	47.40 Bn	1.35 Bn	13.87%
6	Dexcom	34.98 Bn	33.04 Bn	830.00 Mn	19.04%
7	GE HealthCare Technologies	33.73 Bn	31.62 Bn	2.18 Bn	10.84%
8	Koninklijke Philips	26.21 Bn	22.89 Bn	4.55 Bn	6.47%
9	Steris	23.17 Bn	22.69 Bn	684.20 Mn	13.47%
10	Elutia	40.75 Mn	20.85 Mn	1.45 Mn	-315.04%

Download Data